Biodesix Stock Earnings Estimates Decreased by HC Wainwright

Biodesix, Inc. (NASDAQ:BDSX) – Equities researchers at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for Biodesix in a research note issued to investors on Monday, November 9th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($3.13) per share for the year, down from their previous forecast of ($2.72). HC Wainwright has a “Buy” rating and a $34.00 price target on the stock. The consensus estimate for Biodesix’s current full-year earnings is ($2.81) per share. HC Wainwright also issued estimates for Biodesix’s Q4 2026 earnings at ($0.86) EPS, Q1 2027 earnings at ($0.75) EPS, Q2 2027 earnings at ($0.56) EPS, Q3 2027 earnings at ($0.50) EPS, Q4 2027 earnings at ($0.40) EPS and FY2027 earnings at ($2.18) EPS.

Biodesix (NASDAQ:BDSX) last released its earnings results on Thursday, November 5th. The company reported ($0.75) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.75). Biodesix had a negative net margin of 25.74% and a negative return on equity of 513.78%. The business had revenue of $24.04 million during the quarter, compared to the consensus estimate of $27.48 million.

BDSX has been the subject of several other reports. Weiss Ratings upgraded shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 8th. Lake Street Capital dropped their target price on shares of Biodesix from $40.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, November 6th. TD Cowen reaffirmed a “buy” rating and set a $40.00 price target (up from $30.00) on shares of Biodesix in a research report on Tuesday, October 13th. Finally, Canaccord Genuity Group increased their price target on Biodesix from $27.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Biodesix has a consensus rating of “Moderate Buy” and an average target price of $34.20.

Biodesix Stock Down 3.1%

Shares of NASDAQ BDSX opened at $10.02 on Wednesday. The company has a market capitalization of $111.12 million, a P/E ratio of -3.63 and a beta of 0.65. Biodesix has a 52-week low of $5.26 and a 52-week high of $31.97. The company has a debt-to-equity ratio of 5.12, a quick ratio of 2.85 and a current ratio of 2.85. The company’s 50 day moving average price is $24.87 and its 200-day moving average price is $18.89.

Hedge Funds Weigh In On Biodesix

Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in shares of Biodesix during the 2nd quarter worth approximately $970,000. Sei Investments Co. bought a new stake in shares of Biodesix in the 1st quarter valued at $624,000. GSA Capital Partners LLP acquired a new position in shares of Biodesix during the 2nd quarter valued at $1,060,000. Walleye Capital LLC acquired a new position in shares of Biodesix during the 2nd quarter valued at $1,679,000. Finally, AIGH Capital Management LLC bought a new position in Biodesix during the second quarter worth $15,296,000. 20.96% of the stock is currently owned by institutional investors.

Biodesix Company Profile

Biodesix, Inc. is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of lung diseases, including lung cancer. The company combines proprietary molecular diagnostic technologies, clinical data, and artificial intelligence to help physicians assess disease risk and make more informed treatment decisions. Its offerings include blood-based tests designed to help evaluate indeterminate pulmonary nodules, identify patients who may be at higher risk of lung cancer, and support treatment selection and monitoring.